New drug trial targets Cancer's genetic engine
NCT ID NCT03310879
Summary
This study is testing whether the drug abemaciclib can slow or stop the growth of advanced solid tumors that have specific genetic abnormalities. It is for adults with cancers that have mutations in certain genes (CCND1, CCND2, CCND3, CDK4, or CDK6) and for whom standard treatments are no longer effective. The goal is to see if this targeted therapy can control the cancer in people with these specific genetic profiles.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.